New research has revealed for the first time the structure of a protein associated with several anxiety disorders, a discovery that could eventually lead to better drugs. Elly Earls meets the researchers behind the breakthrough to find out more.
Cancer is notoriously frustrating to treat because of the high rate of recurrence and metastasis. In many cases, this may be due to cancer stem cells, which conventional therapies struggle to eradicate. However, researchers at the Manchester Institute of Cancer Sciences have suggested these cells might be defeated by blocking their mitochondrial metabolism, in other words draining their ‘fuel tank’. Lead author Professor Michael Lisanti talks to Abi Millar about what the discovery might mean for future treatments.
The NHS’s approval of Opsumit, a new drug for pulmonary arterial hypertension (PAH), marks a new era for the treatment of this rare and ultimately fatal disease. Elly Earls speaks to Actelion’s Robin Bhattacherjee and consultant physician Dr Luke Howard to find out why.
Boehringer Ingelheim GmbH has announced plans to shutdown its Ben Venue Laboratories unit by the end of the month, cutting 1,100 jobs and putting pressure on the supply of drugs for cancer and other diseases.
Boehringer Ingelheim’s LUME-Lung 1 Phase III clinical trial of novel investigational compound nintedanib has provided a significant and clinically relevant overall survival benefit for advanced non-small cell lung cancer (NSCLC) patients with adenocarcinoma histology.